Document is current

Article History

Received: 30 March 2023

Accepted: 29 September 2023

First Online: 17 October 2023

Competing interests

: M.L. has received honoraria for presentations from Novartis Pharma. Jonathan Timpka has received funding from the Swedish National Government and County Councils through the ALF agreement, the Elsa Schmitz Foundation, and the Swedish Parkinson Foundation. He has received compensation for consultancies from TransPerfect and the Swedish National Board of Health and Welfare, as well as royalties from UNI-MED Verlag. A.B. has nothing to disclose. H.K. was employee of Global Kinetics, Melbourne, Australia. F.G. has received honoraria from AbbVie, BIAL, Merz, and STADA outside the submitted work. M.H. has been a consultant to Global Kinetics (manufacturer of the PKG^®), since 2017. He is a founder of Global Kinetics and an inventor of the PKG^®. Prior to 2017 he was a member of Global Kinetics and received shares in Global Kinetics as reimbursement. G.E. has received honoraria for advisory Boards, consultancy and presentations from AbbVie Pharma, BIAL, Biogen GmbH, Desitin Pharma, STADA Pharma, Neuroderm Inc., Licher GmbH, UCB Pharma, and Zambon Pharma. He has received royalties from Kohlhammer Verlag and Thieme Verlag. P.O. has received funding from AbbVie, Lund University Medical Faculty, Multipark, the Swedish Parkinson Foundation, Health Care Region Skåne, and Åhlens Foundation. He has received honoraria for lectures and expert advice from AbbVie, Bial, Britannia, Ever Pharma, Global Kinetics, Lobsor, Nordic Infucare, Stada, and Zambon. He has received royalties from UNI-MED Verlag. A.S. has received funding from the Deutsche Forschungsgemeinschaft (German Research Association) and the Helmholtz-Association outside the present study. He has received honoraria for presentations/advisory boards/consultations from Global Kinetics Corporation (manufacturer of the PKG^®), Desitin, Lobsor Pharmaceuticals, STADA, Bial, RG Gesellschaft, Zambon, NovoNordisk, and AbbVie outside the present study. He has received royalties from Kohlhammer Verlag and Elsevier Press. He serves as an editorial board member of Stem Cells International.